MPL and autoimmune polyendocrinopathy: Of note, all these primary APS patients received sirolimus monotherapy for TP during the entire follow-up period, without any glucocorticoid, immunosuppressants, intravenous immunoglobulins, thrombopoietin-receptor agonist, etc.